We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Healius Limited is a medical care facilities business based in Australia. Healius shares (HLS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Healius has a trailing 12-month revenue of around $1.9 billion. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $3.2232 - $5.256 |
|---|---|
| 50-day moving average | $5.0049 |
| 200-day moving average | $4.4442 |
| Target price | $2.76 |
| PE ratio | 70.5714 |
| Dividend yield | $0.133 (2.64%) |
| Earnings per share (TTM) | $0.07 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$4.94
| 1 week (2021-09-09) | 2.28% |
|---|---|
| 1 month (2021-08-19) | -5.36% |
| 3 months (2021-06-18) | 12.79% |
| 6 months (2021-03-19) | 21.08% |
| 1 year (2020-09-18) | 48.80% |
|---|---|
| 2 years (2019-09-19) | 53.89% |
| 3 years (2018-09-19) | 70.34% |
| 5 years (2016-09-19) | 35.10% |
Valuing Healius stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Healius's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Healius's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 71x. In other words, Healius shares trade at around 71x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Healius's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $296 million (£0.0 million).
The EBITDA is a measure of a Healius's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.9 billion |
|---|---|
| Operating margin TTM | 13.34% |
| Gross profit TTM | $725.5 million |
| Return on assets TTM | 3.81% |
| Return on equity TTM | 3.5% |
| Profit margin | 2.28% |
| Book value | 3.098 |
| Market capitalisation | $3.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 55.21% of net profits
Recently Healius has paid out, on average, around 55.21% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.73% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Healius shareholders could enjoy a 2.73% return on their shares, in the form of dividend payments. In Healius's case, that would currently equate to about A$0.133 per share.
Healius's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 12 September 2021 (the "ex-dividend date").
Over the last 12 months, Healius's shares have ranged in value from as little as $3.2232 up to $5.256. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Healius's is 1.0684. This would suggest that Healius's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. The company operates through three segments: Pathology, Imaging, and Day Hospitals. It offers diagnostic imaging services, including X-ray, ultrasound, computerized tomography, mammography, magnetic resonance imaging, nuclear medicine, positron emission tomography, and interventional radiology; and private medical laboratory and pathology services. The company also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin, cancer removal, IVF egg collection, and gynaecological surgery services. It operates 2,335 sites, including 2,185 pathology sites; 15 day hospital sites; and 135 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is headquartered in St Leonards, Australia.
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Shares in the lithium producer are up five-fold over the last 12 months.
